Person: SALMAN, ANDAÇ
Loading...
Email Address
Birth Date
Research Projects
Organizational Units
Job Title
Last Name
SALMAN
First Name
ANDAÇ
Name
7 results
Search Results
Now showing 1 - 7 of 7
Publication Metadata only Effectiveness of Omalizumab in Patients with Chronic Inducible Urticaria: real-life experience from two UCARE centres(2021) SALMAN, ANDAÇ; Can, P. K.; Salman, A.; Hoşgören-Tekin, S.; Kocatürk, E.Publication Metadata only What determines the treatment persistence in paediatric psoriasis?(WILEY, 2021) SALMAN, ANDAÇ; Salman, A.Publication Metadata only Remission of chronic spontaneous urticaria following omalizumab with gradually extended dosing intervals: Real-life data(WILEY, 2021) SALMAN, ANDAÇ; Salman, Andac; Aktas, Meryem; Sengun, Ozlem AptiOmalizumab is a well-established treatment option in chronic spontaneous urticaria unresponsive to antihistamines at standard or higher doses. However, characteristics of the remission and relapse following the withdrawal of omalizumab remain largely unknown. We aimed to define the characteristics of remission in CSU following omalizumab with gradually lengthened dosing intervals in this retrospective study of 102 patients who were treated with at least 5 doses of omalizumab between 2015 and 2020. Of 102 patients, 70 (68.6%) showed a CR to omalizumab at standard doses. Omalizumab could be discontinued in 47 of 70 patients using gradually lengthened dosing intervals. Following a mean follow-up duration of 12.2 months, 25 (58.1%) patients were still in remission while 18 (41.9%) had relapse (Follow-up data were not available in 4 patients). The relapses were unresponsive to antihistamines in 14 patients (77.7%), however, retreatment with omalizumab led to complete control of symptoms. The patients younger than 40 were more likely to relapse. Despite the need for comparison with fixed-dosing intervals in larger, prospective studies, the results of this study imply that omalizumab with gradually extended dosing intervals might provide a long duration of remission in CSU.Publication Metadata only Yellow Urticaria(ELSEVIER, 2021) SALMAN, ANDAÇ; Cakici, Ozlem Akin; Sengun, Ozlem Apti; Tekin, Selcen Hosgoren; Salman, AndacPublication Metadata only Visual Dermatology: Koebner's Phenomenon Due to Wet Cupping Therapy(SAGE PUBLICATIONS INC, 2021) SALMAN, ANDAÇ; Gulus-Demirel, Beril; Salman, AndacPublication Metadata only Targeted Therapy for Chronic Spontaneous Urticaria: Rationale and Recent Progress(ADIS INT LTD, 2020) SALMAN, ANDAÇ; Gimenez-Arnau, Ana M.; Salman, AndacChronic spontaneous urticaria (CSU) is characterized by the presence of wheals, angioedema, or both for at least 6 weeks. It may persist for a long time-up to 50% of the patients have been reported to be symptomatic 5 years after the onset. Some patients can suffer more than one episode of CSU during their lifetime. Considering the recurrences, disabling symptoms, and significant impact on quality of life, proper and effective treatment of CSU is critical. The use of antihistamines (AHs) is still the mainstay of treatment. However, given the low rates of response to AHs (38.6% and 63.2% to standard doses and higher doses, respectively), the complete control of symptoms seems difficult to attain. The use of omalizumab for CSU has been a major breakthrough in the care of patients with CSU. However, the partial response and lack of response to omalizumab in a subgroup of patients, as high as 70% in some studies, make the development of alternative treatments desirable. Ever-increasing knowledge on the pathogenesis is making new target molecules available and enabling drug development for CSU. In addition to drug repurposing as in anti-IL-4/13, IL-5, and IL-17 antibodies, novel targeted therapy options such as ligelizumab and Bruton's tyrosine kinase inhibitors are currently undergoing clinical trials and will be available in the near future. This article reviews the current challenges in the treatment of CSU, the pathogenesis and potential target molecules, and the rationale for novel treatments and their rapidly developing status.Publication Metadata only Netherton syndrome: Temporary response to dupilumab(WILEY, 2020) SALMAN, ANDAÇ; Aktas, Meryem; Salman, Andac; Apti Sengun, Ozlem; Comert Ozer, Elif; Hosgoren Tekin, Selcen; Akin Cakici, Ozlem; Demir, Gizem; Ergun, TulinNetherton syndrome (NS) is an orphan disease characterized by congenital ichthyosis, hair abnormalities, and atopy, with limited treatment options. We achieved temporary improvement only during the initial 6 weeks of treatment with dupilumab, which differs from the sustained improvement observed in 2 other recently published cases. Although the clinical presentation of atopy and increased pre-allergic cytokines in NS patients suggest that dupilumab may be beneficial, larger studies are required.